{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:25:52Z","timestamp":1794097552047,"version":"4.8.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have demonstrated substantial therapeutic benefits for patients with Type 2 diabetes mellitus and\/or obesity. Their use has recently expanded rapidly across diverse patient populations. However, GLP-1 RA\u2013associated changes in body composition and skin quality, including premature skin aging and alterations in body contour, may create functional and aesthetic concerns for patients. Effective strategies to address these visible and unwanted effects are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To summarize preclinical and clinical evidence supporting the potential role of AP31, a novel multifunctional micropeptide, in mitigating skin-laxity effects relevant to patients treated with GLP-1 RAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>Preclinical studies have evaluated the biological activity of AP31 across multiple aging-related end points, including inflammatory pathways, extracellular matrix integrity, and age-associated gene expression. In addition, clinical studies have assessed AP31-containing regimens in middle-aged women, with outcomes focused on visible markers of skin aging such as firmness, elasticity, fine lines, wrinkles, facial contour, and structural support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Preclinical investigations demonstrated that AP31 reduced proinflammatory markers, increased key extracellular matrix components, and favorably modulated genes associated with intrinsic skin aging. In clinical studies, AP31-containing regimens produced rapid and visible improvements in multiple parameters of skin aging, including enhanced firmness and elasticity, reduction in fine lines and wrinkles, improvement in jawline definition, global facial lift, and reduced prominence of nasolabial folds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>AP31 shows promising biological and clinical activity in improving visible signs of skin aging. While current findings are encouraging in the context of normal aging, randomized controlled trials are warranted to further establish the efficacy of AP31 for patients experiencing skin-related changes associated with GLP-1 RA use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000005181","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:00:41Z","timestamp":1780045241000},"page":"S16-S22","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A Novel Cosmetic Anti-inflammatory Peptide With Firming and Lifting Benefits: The Potential for Adjunctive Care for Skin Laxity Associated With Weight Loss"],"prefix":"10.1097","volume":"52","author":[{"given":"Toni A.","family":"Lisante","sequence":"first","affiliation":[{"name":"All authors are affiliated with the Kenvue Brands LLC, Summit, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Green","sequence":"additional","affiliation":[{"name":"All authors are affiliated with the Kenvue Brands LLC, Summit, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassidy","family":"Hubert","sequence":"additional","affiliation":[{"name":"All authors are affiliated with the Kenvue Brands LLC, Summit, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramine","family":"Parsa","sequence":"additional","affiliation":[{"name":"All authors are affiliated with the Kenvue Brands LLC, Summit, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Patel Shah","sequence":"additional","affiliation":[{"name":"All authors are affiliated with the Kenvue Brands LLC, Summit, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunaira","family":"Shuja","sequence":"additional","affiliation":[{"name":"All authors are affiliated with the Kenvue Brands LLC, Summit, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guia","family":"Sylianteg","sequence":"additional","affiliation":[{"name":"All authors are affiliated with the Kenvue Brands LLC, Summit, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260730","doi-asserted-by":"crossref","first-page":"850\u2013P","DOI":"10.2337\/db24-850-P","article-title":"850-P: trends in GLP-1RA use among individuals with type 2 diabetes (T2D) and\/or obesity\u2014insights from a nationwide electronic health record system, 2010\u20132023","volume":"73","author":"Li","year":"2024","journal-title":"Diabetes"},{"key":"R2-20260730","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jval.2025.06.001","article-title":"Use and potential misuse of glucagon-like peptide-1 receptor agonists in France: a nationwide cohort study","volume":"28","author":"du Soulier","year":"2025","journal-title":"Value Health"},{"key":"R3-20260730","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.37765\/ajmc.2025.89778","article-title":"Trends in glucagon-like peptide 1 receptor agonist prescribing patterns","volume":"31","author":"Ukhanova","year":"2025","journal-title":"Am J Manag Care"},{"key":"R4-20260730","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000544023","article-title":"Dermatologic implications of glucagon-like peptide-1 receptor agonist medications","volume":"11","author":"Burke","year":"2025","journal-title":"Skin Appendage Disord"},{"key":"R5-20260730","doi-asserted-by":"crossref","first-page":"e16716","DOI":"10.1111\/jocd.16716","article-title":"The role of GLP-1 agonists in esthetic medicine: exploring the impact of semaglutide on body contouring and skin health","volume":"24","author":"Haykal","year":"2025","journal-title":"J Cosmet Dermatol"},{"key":"R6-20260730","doi-asserted-by":"crossref","first-page":"NP809","DOI":"10.1093\/asj\/sjae132","article-title":"Decoding the implications of glucagon-like peptide-1 receptor agonists on accelerated facial and skin aging","volume":"44","author":"Ridha","year":"2024","journal-title":"Aesthet Surg J"},{"key":"R7-20260730","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1007\/s13555-025-01537-5","article-title":"Benefit-risk assessment of GLP-1 receptor agonists: implications for dermatologists and plastic surgeons","volume":"15","author":"Cedirian","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R8-20260730","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s12020-025-04293-w","article-title":"GLP-1RA and the possible skin aging","volume":"89","author":"Paschou","year":"2025","journal-title":"Endocrine"},{"key":"R9-20260730","doi-asserted-by":"crossref","first-page":"52","DOI":"10.33590\/emjdermatol\/TYEW1122","article-title":"Increased incidence and risk of hair loss with glucagon-like peptide 1 receptor agonists: a real-world multicentre cohort study","volume":"13","author":"Akiska","year":"2025","journal-title":"EMJ Dermatol"},{"key":"R10-20260730","doi-asserted-by":"crossref","first-page":"e7282","DOI":"10.1097\/GOX.0000000000007282","article-title":"Interest in facial volume restorative procedures with the rise in \u201cOzempic Face\u201d: a google trends analysis","volume":"13","author":"Mnajjed","year":"2025","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R11-20260730","doi-asserted-by":"crossref","first-page":"ojaf056","DOI":"10.1093\/asjof\/ojaf056","article-title":"\u201cOzempic Face\u201d in plastic surgery: a systematic review of the literature on GLP-1 receptor agonist mediated weight loss and analysis of public perceptions","volume":"7","author":"Daneshgaran","year":"2025","journal-title":"Aesthet Surg J Open Forum"},{"key":"R12-20260730","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/asj\/sjae085","article-title":"Prevalence patterns of body contouring procedures among injectable glucagon-like peptide-1 receptor agonist users","volume":"44","author":"Toms","year":"2024","journal-title":"Aesthet Surg J"},{"key":"R13-20260730","doi-asserted-by":"crossref","first-page":"23","DOI":"10.36849\/JDD.8786","article-title":"Acetyl dipeptide-31 amide: a novel cosmetic anti-inflammatory peptide that demonstrates anti-aging, firming, and lifting benefits","volume":"24","author":"Edison","year":"2025","journal-title":"J Drugs Dermatol"},{"key":"R14-20260730","doi-asserted-by":"crossref","first-page":"51181s4","DOI":"10.36849\/JDD.51181","article-title":"INDIVIDUAL ARTICLE: a scientific approach to defining, evaluating, and treating pre-aging with a cosmetic regimen containing a novel cosmetic peptide, acetyl dipeptide-31 amide (AP31)","volume":"24","author":"Farris","year":"2025","journal-title":"J Drugs Dermatol"},{"key":"R15-20260730","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/pharmaceutics17091115","article-title":"Semaglutide enhances cellular regeneration in skin and retinal cells in vitro","volume":"17","author":"Anastasiou","year":"2025","journal-title":"Pharmaceutics"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:02:55Z","timestamp":1785384175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":15,"journal-issue":{"issue":"6S","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000005181","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}